Exhibit
|
Description
|
99.1
|
News Release dated
February 4, 2022 - Intellipharmaceutics Reports Director Election
Results
|
99.2
|
Report on Voting
Results
|
|
|
Intellipharmaceutics
International Inc.
(Registrant)
/s/
Dr. Amina Odidi
|
Date:
February 4, 2022
|
|
Dr.
Amina Odidi
President,
Chief Operating Officer and Acting Chief Financial
Officer
|
Name of Nominee
|
Votes For
|
Votes Withheld
|
Dr.
Isa Odidi
|
10,810,980
|
2,196,903
|
|
83.1%
|
16.9%
|
Dr.
Amina Odidi
|
10,811,457
|
2,196,426
|
|
83.1%
|
16.9%
|
Bahadur
Madhani
|
11,011,116
|
1,996,767
|
|
84.6%
|
15.4%
|
Norman
Betts
|
11,014,364
|
1,993,519
|
|
84.7%
|
15.3%
|
Shawn
Graham
|
11,025,529
|
1,982,354
|
|
84.8%
|
15.2%
|
|
Description of Matter
|
|
Outcome of Vote
|
1.
|
Resolution to elect
five directors, being Dr. Isa Odidi, Dr. Amina Odidi, Bahadur
Madhani, Norman Betts and Shawn Graham, as proposed in the
management information circular for the Meeting.
|
|
The five nominees
were elected as directors of the Corporation to serve until the
next annual meeting of shareholders or until their successors are
elected or appointed. This vote was conducted by a show of hands.
The scrutineer’s report on voting results is attached as
Schedule “A” hereto.
|
2.
|
Resolution to
reappoint auditor and to authorize the directors to fix the
remuneration thereof, as proposed in the management information
circular for the Meeting.
|
|
MNP LLP was
reappointed auditor of the Corporation until the next annual
meeting of shareholders and the directors were authorized to fix
the remuneration to be paid to the auditor. This vote was conducted
by a show of hands. The scrutineer’s report on voting results
is attached as Schedule “A” hereto.
|
3.
|
Resolution to
approve all unallocated options, rights and entitlements under the
Company’s stock option plan as more particularly described in
the Management Proxy Circular for the meeting.
|
|
As proposed in the
Circular, the shareholders ratified the special resolution to
approve all the unallocated options, rights and entitlements under
the Company’s stock option plan as more particularly
described in the Management Proxy Circular for the meeting. The
scrutineer’s report on voting results is attached as Schedule
“A” hereto.
|
|
DATED
as of the 4th day of February,
2022.
INTELLIPHARMACEUTICS
INTERNATIONAL INC.
(signed)
“Amina
Odidi”
Amina
Odidi
President/Acting
Chief Financial Officer
|
Nominees
|
For
|
%
|
Withheld
|
%
|
Dr. Isa
Odidi
|
10,810,980
|
83.11%
|
2,196,903
|
16.89%
|
Dr. Amina
Odidi
|
10,811,457
|
83.11%
|
2,196,426
|
16.89%
|
Bahadur
Madhani
|
11,011,116
|
84.65%
|
1,996,767
|
15.35%
|
Norman
Betts
|
11,014,364
|
84.67%
|
1,993,519
|
15.33%
|
Shawn
Graham
|
11,025,529
|
84.76%
|
1,982,354
|
15.24%
|
|
|
|
|
|
For:
|
16,043,631
|
95.93%
|
Withheld:
|
680,479
|
4.07%
|
Total:
|
16,724,110
|
100%
|
For:
|
10,323,672
|
79.36%
|
Withheld:
|
2,684,213
|
20.64%
|
Total:
|
13,007,885
|
100%
|
For:
|
9,740,643
|
78.40%
|
Withheld:
|
2,684,213
|
21.60%
|
Total:
|
12,424,856
|
100%
|
/s/
"Helen Kim"
Helen Kim
|
/s/ “Megan
Rocha”
Meghan
Rocha
|